Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12301006 | 0.88 | LMNA (0.66) | ADORA3NPC1RAB9AMAPTKMT2A | |
| SCHEMBL1821135 | 0.88 | KMT2A (0.69) | ADORA3NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL12302712 | 0.85 | MEN1 (0.67) | ADORA3NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL12302701 | 0.83 | SMN1; SMN2 (0.63) | ADORA3NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL12301134 | 0.83 | ADORA3 (0.71) | ADORA3NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL4749713 | 0.82 | NPC1 (0.61) | NPC1RAB9AMAPTMAPK1KMT2A | |
| SCHEMBL18029512 | 0.81 | NPC1 (0.69) | NPC1RAB9AMAPTMAPK1KMT2A | |
| SCHEMBL11139020 | 0.81 | CSNK2A1 (0.66) | NPC1RAB9AMAPTMAPK1KMT2A | |
| SCHEMBL18029497 | 0.81 | MEN1 (0.69) | NPC1RAB9AMAPTMAPK1KMT2A | |
| SCHEMBL12301483 | 0.81 | SMN1; SMN2 (0.63) | ADORA3NPC1RAB9AMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| CN-104254534-B | Modulators of HEC1 activity and methods thereof | 泰纬生命科技股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| US-8999983-B2 | Modulators of Hec1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-04-07 | — | — | US | disclosed |
| US-20150057281-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2015-02-26 | — | — | US | disclosed |
| US-8946268-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS, INC. (TW) | 2015-02-03 | — | — | US | disclosed |
| CN-104254534-A | Modulators of HEC1 activity and methods thereof | TAIVEX THERAPEUTICS CORP | 2014-12-31 | — | — | CN | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-07-25 | — | — | US | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190312-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | ADORA3 4717/4885NPC1 1198/4885RAB9A 3066/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | ADORA3 4717/4885NPC1 1198/4885RAB9A 3066/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | ADORA3 4717/4885NPC1 1198/4885RAB9A 3066/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | ADORA3 4717/4885NPC1 1198/4885RAB9A 3066/4885 |
| US-20150057281-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | ADORA3 4723/4885NPC1 1402/4885RAB9A 3097/4885 |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | WEE1, WEE2, NEK11 | ADORA3 4723/4885NPC1 1402/4885RAB9A 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.